Targeting ErbB2 aberrations in non-small cell lung cancer

Xuan Ge, Sara Tariq, Haiying Cheng, Balazs Halmos

Research output: Contribution to journalReview articlepeer-review


Human epidermal growth factor 2 (HER2 or ErbB2) mutations in lung cancer are oncogenic drivers similar to epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancers. Until recently, ErbB2-mutant lung cancers have generally been resistant to various targeted agents. However, a new wave of ErbB2-targeting drugs has shown promise for this subset. We highlight a case of a patient with an ErbB2-mutant lung cancer with an exon 20 YVMA insertion who had a good response to poziotinib and review the current literature on the methods of testing for ErbB2 mutations and the efficacy of various known and emerging targeted agents.

Original languageEnglish (US)
Article number27
JournalPrecision Cancer Medicine
Issue numberNovember
StatePublished - Nov 2019


  • ErbB2 mutations
  • Exon 20 YVMA insertion
  • Non-small cell lung cancer (NSCLC)
  • Poziotinib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Oncology(nursing)
  • Pharmacology (medical)
  • Surgery
  • Anesthesiology and Pain Medicine


Dive into the research topics of 'Targeting ErbB2 aberrations in non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this